Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth

Neuron Glia Biology

Volumn 1, Issue 2, 2004, Pages 165-176

  Gondi, Christopher S ^a   Lakka, Sajani S ^a   Dinh, Dzung H ^a   Olivero, William C ^b   Gujrati, Meena ^b   Rao, Jasti S ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

angiogenesis; gliomas; invasion; RNA interference

Indexed keywords

EID: 85022917932     PISSN: 1740925X     EISSN: 17410533     Source Type: Journal    
DOI: 10.1017/S1740925X04000237     Document Type: Article

References (67)

1. Alemany R., Gomez-Manzano C., Balague C., Yung W.K., Curiel D.T., Kyritsis A.P. and Fueyo J. (1999) Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Experimental Cell Research 252,1-12.
2. Alonso D.F., Farias E.F., Ladeda V., Davel L., Puricelli L. and Bal de Kier J.E. (1996) Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Research Treatment 40, 209–223.
3. Alonso D.F., Tejera A.M., Farias E.F., Bal de Kier J.E. and Gomez D.E. (1998) Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. Anticancer Research 18,4499-4504.
4. Andreasen P.A., Kjoller L., Christensen L. and Duffy M.J. (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. International Journal of Cancer 72,1-22.
5. Behzadian M. A., Windsor L.J., Ghaly N., Liou G., Tsai N.T. and Caldwell R.B. (2003) VEGF-induced paracellular permeability in cultured en-dothelial cells involves urokinase and its receptor. FASEB Journal 17, 752–754.
6. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P. et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology 2, 737–744.
7. Bertrand J.R., Pottier M., Vekris A., Opolon P., Maksimenko A. and Malvy C. (2002) Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochemical Biophysical Research Communications 296,1000-1004.
8. Blasi F (1999) The urokinase receptor. A cell surface, regulated chemokine. APMIS 107, 96–101.
9. Bugge T.H., Kombrinck K.W., Xiao Q., Holmback K., Daugherty C.C., Witte D.P. and Degen J.L. (1997) Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood 90, 4522–4531.
10. Busso N., Masur S.K., Lazega D., Waxman S. and Ossowski L. (1994) Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. Journal of Cell Biology 126, 259–270.
11. Caplen N.J., Parrish S., Imani F., Fire A. and Morgan R.A. (2001) Specific inhibition of gene expression by small double-stranded RNAs in inver-tebrate and vertebrate systems. Proceedings of the National Academy of Sciences of the United States of America 98, 9742–9747.
12. Carmell M.A., Zhang L., Conklin D.S., Hannon G.J. and Rosenquist T.A. (2003) Germline transmission of RNAi in mice. Nature Structural Biology 10, 91–92.
13. Carriero M.V., Del Vecchio S., Capozzoli M., Franco P., Fontana L., Zannetti A., Botti G., D’Aiuto G. et al. (1999) Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Research 59, 5307–5314.
14. Carroll V.A. and Binder B.R. (1999) The role of the plasminogen activation system in cancer. Seminars in Thrombosis and Hemostasis 25, 183–197.
15. Chandrasekar N., Jasti S., Alfred-Yung W.K., Ali-Osman F., Dinh D.H., Olivero W.C., Gujrati M., Kyritsis A.P. et al. (2000) Modulation of endothelial cell morphogenesis in vitro by MMP-9 during glial—endothelial cell interactions. Clinical Experimental Metastasis 18, 337–342.
16. Choe G., Park J.K., Jouben-Steele L., Kremen T.J., Liau L.M., Vinters H.V., Cloughesy T.F. and Mischel P.S. (2002) Active matrix metal-loproteinase 9 expression is associated with primary glioblastoma subtype. Clinical Cancer Research 8, 2894–2901.
17. Coussens L.M., Tinkle C.L., Hanahan D. and Werb Z. (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogen-esis. Cell 103, 481–490.
18. Crowley C.W., Cohen R.L., Lucas B.K., Liu G., Shuman M.A. and Levinson A.D. (1993) Prevention of metastasis by inhibition of the urokinase receptor. Proceedings of the National Academy of Sciences of the United States of America 90, 5021–5025.
19. Dewerchin M., Nuffelen A.V., Wallays G., Bouche A., Moons L., Carmeliet P., Mulligan R.C. and Collen D. (1996) Generation and characterization of urokinase receptor-deficient mice. Journal of Clinical Investigation 97, 870–878.
20. Egeblad M. and Werb Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2, 161–174.
21. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K. and Tuschl T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498.
22. Ellis V., Behrendt N. and Dano K. (1991) Plasminogen activation by receptor-bound urokinase A kinetic study with both cell-associated and isolated receptor. Journal of Biological Chemistry 266,12752-12758.
23. Ellis V., Pyke C., Eriksen J., Solberg H. and Dano K. (1992) The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Annals of the New York Academy of Sciences 667,13-31.
24. Engelhard H., Narang C., Homer R. and Duncan H. (1996) Urokinase antiaense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity. Biochemical Biophysical Research Communication 227, 400–405.
25. Evans D.M., Sloan-Stakleff K., Aryan M. and Guyton D.P. (1998) Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride. Clinical Experimental Metastasis 16, 353–357.
26. Forsyth P.A., Wong H., Laing T.D., Rewcastle N.B., Morris D.G., Muzik H., Leco K.J., Johnston R.N. et al. (1999) Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MTi-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. British Journal of Cancer 79,1828-1835.
27. Giese A. and Westphal M. (1996) Glioma invasion in the central nervous system. Neurosurgery 39, 235–250.
28. Gladson C.L., Pijuan-Thompson V., Olman M.A., Gillespie G.Y. and Yacoub I.Z. (1995) Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. American Journal of Pathology 146, 1150–1160.
29. Go Y., Chintala S.K., Mohanam S., Gokaslan Z., Venkaiah B., Bjerkvig R., Oka K., Nicolson G.L. et al. (1997) Inhibition of in vivo tumori-genicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Clinical Experimental Metastasis 15, 440–446.
30. Gondi C.S., Lakka S.S., Yanamandra N., Olivero W.C., Dinh D.H., Gujrati M., Tung C.H., Weissleder R. et al. (2004) Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Research 64, 4069–4077.
31. Gondi C.S., Lakka S.S., Yanamandra N., Siddique K., Dinh D.H., Olivero W.C., Gujrati M. and Rao J.S. (2003) Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 22, 5967–5975.
32. Gutierrez L.S., Schulman A., Brito-Robinson T., Noria F., Ploplis V.A. and Castellino F.J. (2000) Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-i. Cancer Research 60, 5839–5847.
33. Hedberg K.K., Stauff C., Hoyer-Hansen G., Ronne E. and Griffith O.H. (2000) High-molecular-weight serum protein complexes differentially promote cell migration and the focal adhesion localization of the urokinase receptor in human glioma cells. Experimental Cell Research 257, 67–81.
34. Holst-Hansen C., Johannessen B., Hoyer-Hansen G., Romer J., Ellis V. and Brunner N. (1996) Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clinical Experimental Metastasis 14, 297–307.
35. Hua J. and Muschel R.J. (1996) Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Research 56, 5279–5284.
36. Jarrard D.F., Hansen N.M., Patai B. and Rukstalis D.B. (1995) Urokinase plasminogen activator is necessary but not sufficient for prostate cancer cell invasion. Invasion Metastasis 15,34-45.
37. Jo M., Thomas K.S., O’Donnell D.M. and Gonias S.L. (2003) Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. Journal of Biological Chemistry 278,1642-1646.
38. Kajita M., Itoh Y., Chiba T., Mori H., Okada A., Kinoh H. and Seiki M. (2001) Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. Journal of Cell Biology 153, 893–904.
39. Konakova M., Hucho F. and Schleuning W.D. (1998) Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. European Journal of Biochemistry 253, 421–429.
40. Kondraganti S., Mohanam S., Chintala S.K., Kin Y., Jasti S.L., Nirmala C., Lakka S.S., Adachi Y. et al. (2000) Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Research 60, 6851–6855.
41. Lakka S.S., Gondi C.S., Yanamandra N., Dinh D.H., Olivero W.C., Gujrati M. and Rao J.S. (2003) Synergistic down-regulation of uroki-nase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Research 63, 2454–2461.
42. Lakka S.S., Gondi C.S., Yanamandra N., Olivero W.C., Dinh D.H., Gujrati M. and Rao J.S. (2004) Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23, 4681–4689.
43. Lakka S.S., Jasti S.L., Gondi C., Boyd D., Chandrasekar N., Dinh D.H., Olivero W.C., Gujrati M. et al. (2002) Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 21, 5601–5608.
44. Lakka S.S., Jasti S.L., Kyritsis A.P., Yung W.K., Ali-Osman F., Nicolson G.L. and Rao J.S. (2000) Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades. Clinical Experimental Metastasis 18, 245–252.
45. Lakka S.S., Rajan M., Gondi C., Yanamandra N., Chandrasekar N., Jasti S.L., Adachi Y., Siddique K. et al. (2002) Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 21, 8011–8019.
46. Lampert K., Machein U., Machein M.R., Conca W., Peter H.H. and Volk B. (1998) Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. American Journal of Pathology 153, 429–437.
47. Li H., Lu H., Griscelli F., Opolon P., Sun L.Q., Ragot T., Legrand Y., Belin D. et al. (1998) Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Therapy 5,1105-1113.
48. Matsuzawa K., Fukuyama K., Hubbard S.L., Dirks P.B. and Rutka J.T. (1996) Transfection of an invasive human astrocytoma cell line with a TIMP-i cPNA: modulation of astrocytoma invasive potential. Journal of Neuropathology and Experimental Neurology 55, 88–96.
49. Min H. Y., Doyle L.V., Vitt C.R., Zandonella C.L., Stratton-Thomas J.R., Shuman M.A. and Rosenberg S. (1996) Urokinase receptor antago-nists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Research 56, 2428–2433.
50. Miyagishi M. and Taira K. (2002) U6 promoter-driven siRNAs with four uridine 3’ overhangs efficiently suppress targeted gene expression in mammalian cells. Nature Biotechnology 20, 497–500.
51. Mohan P.M., Chintala S.K., Mohanam S., Gladson C.L., Kim E.S., Gokaslan Z.L., Lakka S.S., Roth J.A. et al. (1999) Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Research 59,3369-3373.
52. Mohanam S., Chandrasekar N., Yanamandra N., Khawar S., Mirza F., Dinh D.H., Olivero W.C. and Rao J.S. (2002) Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator. Oncogene 21,7824-7830.
53. Mohanam S., Chintala S.K., Go Y., Bhattacharya A., Venkaiah B., Boyd D., Gokaslan Z.L., Sawaya R. and Rao J.S. (1997) In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 14,1351-1359.
54. Mohanam S., Jasti S.L., Kondraganti S.R., Chandrasekar N., Kin Y., Fuller G.N., Lakka S.S., Kyritsis A.P. et al. (2001) Stable transfection of urokinase-type plasminogen activator antisense construct modu-lates invasion of human glioblastoma cells. Clinical Cancer Research 7, 2519–2526.
55. Mohanam S., Wang S.W., Rayford A., Yamamoto M., Sawaya R., Nakajima M., Liotta L.A., Nicolson G.L. et al. (1995) Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clinical and Experimental Metastasis 13, 57–62.
56. Tang H., Kerins D.M., Hao Q., Inagami T. and Vaughan D.E. (1998) The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. Journal of Biological Chemistry 273,18268-18272.
57. Tonn J.C., Kerkau S., Hanke A., Bouterfa H., Mueller J.G., Wagner S., Vince G.H. and Roosen K. (1999) Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. International Journal of Cancer 80, 764–772.
58. Vallera D.A., Li C., Jin N., Panoskaltsis-Mortari A. and Hall W.A. (2002) Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. Journal of the National Cancer Institute 94, 597–606.
59. Werb Z., Ashkenas J., MacAuley A. and Wiesen J.F. (1996) Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution and carcinogenesis. Brazil Journal of Medical Biology Research 29,1087-1097.
60. Williams B.R. (1997) Role of the double-stranded RNA-activated protein kinase (PKR) in cell regulation. Biochemical Society Transactions 25, 509–513.
61. Yamamoto M., Sawaya R., Mohanam S., Bindal A.K., Bruner J.M., Oka K., Rao V.H., Tomonaga M. et al. (1994) Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Research 54,3656-3661.
62. Yamamoto M., Sawaya R., Mohanam S., Rao V.H., Bruner J.M., Nicolson G.L. and Rao J.S. (1994) Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Research 54,5016-5020.
63. Yao J., Xiong S., Klos K., Nguyen N., Grijalva R., Li P. and Yu D. (2001) Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-betai in human breast cancer cells. Oncogene 20, 8066–8074.
64. Yu Q., Grammatikakis N. and Toole B.P. (1996) Expression of multiple CD44 isoforms in the apical ectodermal ridge of the embryonic mouse limb. Developmental Dynamics 207, 204–214.
65. Yu Q. and Stamenkovic I. (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Development 14,163-176.
66. Yu W., Kim J. and Ossowski L. (1997) Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. Journal of Cell Biology 137, 767–777.
67. Zamore P.D. (2001) RNA interference: listening to the sound of silence. Nature Structural Biology 8, 746–750.